FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:511-512 February 3, 2005 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bennett, C. L. PubMed Citation

To the Editor: Bennett et al. (Sept. 30 issue)¹ calculated the "incidence" of pure red-cell aplasia among patients receiving epoetin therapy by reviewing reports from the Adverse Event Reporting System of the Food and Drug Administration (FDA). The calculation of incidence rates of pure red-cell aplasia requires complete ascertainment of new cases of this condition in a defined population at risk per unit of time. The completeness of case ascertainment when the FDA's system is used is usually low because that system is based on passive reporting. In addition, some of the 208 cases lacking antibody data and excluded by . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.